Novo Nordisk announced a strategic partnership with OpenAI aimed at transforming how medicines are discovered, developed, and delivered, while embedding advanced AI capabilities across its global operations.
The collaboration will leverage OpenAI’s technology to analyze complex biomedical datasets, identify promising drug candidates, and significantly reduce the time required to move from research to patient. The initiative is designed to accelerate the development of new therapies, particularly for chronic conditions such as obesity and diabetes.
As part of the partnership, Novo Nordisk will integrate AI across multiple functions, including research and development, manufacturing, supply chain, and commercial operations. Pilot programs are expected to begin immediately, with full-scale integration targeted by the end of 2026.
A key component of the agreement includes upskilling Novo Nordisk’s global workforce, enhancing AI literacy and enabling employees to apply advanced tools to improve productivity and decision-making. The partnership also emphasizes strict data governance, human oversight, and compliance measures to ensure responsible and ethical use of AI technologies.
The move builds on Novo Nordisk’s broader efforts to expand its AI capabilities through collaborations with technology partners and research organizations, positioning the company at the forefront of digital transformation in healthcare.
KEY QUOTES:
“This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare. There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives.”
“Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before.”
Mike Doustdar, President And CEO, Novo Nordisk
“AI is reshaping industries and in life sciences, it can help people live better, longer lives. This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
Sam Altman, CEO, OpenAI
